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The Stroke Therapy Academic Industry Roundtable (STAIR) provided initial (in 1999) and updated (in 2009) recommendations
with the goal of improving preclinical stroke therapy assessment and to increase the translational potential of experimental
stroke treatments. It is important for preclinical stroke researchers to frequently consider and revisit these concepts, especially
since promising experimental stroke treatments continue to fail in human clinical trials. Therefore, this paper will focus on
considerations for several key aspects of preclinical stroke studies including the selection and execution of the animal stroke
model, drug/experimental treatment administration, and outcome measures to improve experimental validity and translation
potential. Specific points of interest discussed include the incorporation of human comorbid conditions and drugs, the benefits
of defining a proposed mechanism of action, replication of results using multiple methods, using clinically relevant routes of
administration and treatment time windows, and performing and reporting good experimental methods to reduce bias such as, as
suggested by the updated STAIR recommendations, sample size calculations, randomization, allocation concealment, blinding, and
appropriate inclusion/exclusion criteria. It is our hope that reviewing and revisiting these considerations will benefit researchers
in their investigations of stroke therapies and increase the likelihood of translational success in the battle against stroke.
1. Introduction
Stroke is a leading cause of death and adult disability in
the USA. A tremendous societal burden, stroke affects the
lives of approximately 795,000 people each year, and costs
reach 10s of billions annually [1]. Unfortunately, however,
despite decades of research, FDA approved care for ischemic
stroke, the most common type of stroke that results from an
obstruction (typically a blood clot) blocking a cerebral blood
vessel, remains tissue plasminogen activator (tPA, originally
approved in 1996) and endovascular clot retrieval/removal
techniques including the MERCI device and PENUMBRA
system (approved in 2004 and 2008, resp.) [2]. Furthermore,
tPA administration must follow clinical validation that the
stroke is ischemic and not hemorrhagic, is restricted to 3–
4.5 hrs after stroke onset, and risks hemorrhagic transfor-
mation, whereas devices require equipment and expertise
[3]. Importantly, many stroke treatments have benefitted
or seemingly cured stroke in animal models, but have
ultimately failed in their translation to clinical trials. This has
resulted in a waste of resources and loss of enthusiasm for
novel approaches to stroke therapy and therefore necessitates
discussion on how to surmount this tremendous barrier to
science and medicine.
Increasing the quality of preclinical studies to overcome
failed translation was the general goal of the Stroke Ther-
apy Academic Industry Roundtable (STAIR) when it first
gave “Recommendations for standards regarding preclinical
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neuroprotective and restorative drug development” in 1999
and updated recommendations in 2009 [4, 5]. Unfortunately,
thirteen years since the original STAIR recommendations, we
still face failure in developing new clinical stroke therapies.
Although the STAIR recommendations are perhaps more
widely known today, potential stroke therapies have not
been subjected to more thorough preclinical evaluation.
Furthermore, preclinical studies show huge variation in
methodology. For example, in 54 studies examined, Philip et
al. found 8 models of focal ischemia, 15 species, 6 histological
stains for infarct size, and 19 behavioral tests in nonprimates
[6]. Therefore, revisiting the STAIR recommendations to
modify current practices/habits based on new considerations
and knowledge may improve the odds of not being “lost
in translation.” To that end, we use the STAIRs as a
platform to consider potential limitations of preclinical
stroke investigations, as well as make suggestions as to how
such limitations might be overcome.
2. Animal Model
Selecting the proper animal model amongst the large variety
available to the preclinical stroke researcher should be done
considering the following: (1) the species and strain, (2)
the treatment’s proposed mechanism of action, and (3)
the incorporation of human comorbid conditions. The
STAIR typically recommends using rats first, unless using
genetically modified (e.g., transgenic, knockout) mice,
and then replicating results in at least one other species,
preferably gyrencephalic species and optimally nonhuman
primates [4].
2.1. The Species and Strain. Importantly, one should not
assume that inducing a similar surgical manipulation that is
well characterized in one species (usually rat) will completely
translate to another species at the cellular and molecular
levels of pathophysiology. For example, the stereotactic
injection of endothelin-1 to induce transient vasospasm
and resultant occlusion of a cerebral blood vessel, routinely
performed in rats, produces no infarct when administered
alone in mice [7]. This principle also applies to differences
between laboratory animal strains [8] and between genet-
ically modified animals and wild types. Reasons for this
discrepancy could include, for example, differences in neu-
rovascular anatomy or collateral circulation that could affect
the size of the tissue subjected to ischemia or the efficacy
of compensatory mechanisms to reperfuse the ischemic area
[9]. Indeed, in a global cerebral ischemia model, MF1 mice
had less neuronal damage and ischemic stress, higher blood
pressure, and greater Circle of Willis plasticity compared to
the more commonly studied C57Bl/6J mice [10]. However,
it has been argued that rodent ischemia consequences
do closely replicate human pathobiology and that rodent
models have similar vasculature to humans, whereas the
largest disadvantages of rodent models are that they are
not gyrencephalic, that white matter makes up a larger
proportion in the human than the rodent brain, and that
variability from rodent to rodent is actually too consistent to
translate well to the heterogeneous human population that
experiences stroke and is included in clinical trials (reviewed
in Willing et al., 2009) [11]. Conversely, even within a single
mouse strain, differences in the completeness of the Circle of
Willis exist, leading some researchers to bypass this anatomic
variability with a distal middle cerebral artery occlusion
stroke model [12]. Finally, a practical consideration for
model choice is how costly the experimental treatment is to
the researcher. For example, a 1 mg/kg treatment dose would
require more mass of drug to administer in a rat than in a
mouse.
2.2. The Treatment’s Proposed Mechanism of Action. As
mechanisms of experimental stroke treatments may not
translate to humans, it is logical to suggest that nonhuman
primates, potentially the closest model to humans for stroke
experimentation, should be used to perhaps minimize this
problem. Indeed, similar stroke models (e.g., MCA occlusion
models, autologous embolic models, photothrombosis, etc.)
to rodents and behavioral tests to humans are available in
lissencephalic and gyrencephalic nonhuman primates, where
the Macaca fascicularis may be a good model given its
gyrencephalic brain, relatively low level of collateralization,
and ease of inducing stroke [13]. However, relatively few
researchers today have the necessary experience, facilities, or
access/approval to perform nonhuman primate work. Also,
ethical considerations, expense, and subsequent difficulty of
powering such studies with sufficient numbers of animals for
valid statistical analysis are substantial. Fortunately, rodents
are relatively affordable for experimental stroke study and
can provide a source of genetic manipulation useful as proof-
of-concept for the treatment’s mechanism of action. These
genetic manipulations would perhaps ideally be performed
in both positive and negative directions, for example, with
transgenic animals that overexpress a component of the
mechanism (positive animal manipulation) or hypomorph,
knockdown, knockout, or dominant-negatives (negative
animal manipulation). Additionally, more sophisticated and
specific techniques could be performed including cell-
specific or inducible genetic manipulations, for example,
using the Tet-on system. Defining a therapy’s proposed
mechanism of action is important for clinical translation par-
ticularly if it is known that similar mechanisms might occur
in humans, although this is not a guarantee for successful
clinical translation. Furthermore, such knowledge could help
predict potential deleterious treatment side effects; however,
side effects (or lack thereof) in an animal model also may or
may not translate to humans. Additionally, if a mechanism is
defined, one could test another therapy that is more specific
for that mechanism or (potentially easier for translation) test
a currently FDA approved drug that is known to operate
under the desired mechanism.
2.3. The Incorporation of Human Comorbid Conditions. This
is likely the most important consideration in the selection
of an animal model to increase the translation potential of
preclinical stroke studies. Comorbid conditions for stroke
primarily include older age, hypertension, diabetes, and
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hypercholesterolemia, emphasized in the updated STAIR rec-
ommendations as necessary to include in additional studies
after studying young healthy males [5], as well as metabolic
syndrome, heart disease (especially atrial fibrillation), smok-
ing, and high alcohol consumption [1, 14]. These conditions
may strongly influence the pathophysiology and endogenous
response to stroke. Therefore, comorbid conditions should
be incorporated into preclinical studies and compounded
with one another as much as possible to increase translation
potential. For example, an 18-month aged mouse with
hypertension and diabetes would more accurately represent
the comorbidity often seen in human stroke patients than the
3-4 month healthy young adult mice typically used in pre-
clinical studies. Additionally, studies should also incorporate
more testing in females, as the susceptibility, processes and
responses to stroke differ between genders [15, 16]. In fact,
women have a higher lifetime risk of stroke among those 55
to 75 years of age, 20-21% compared to 14–17% in men [1],
and suffer a higher 30-day mortality rate, 20% compared to
14% in men [17]; however, females remain underrepresented
in experimental research.
Finally, potential stroke patients are more likely to be
taking drugs to treat comorbid conditions, and these drugs
could potentially interact directly or physiologically with
experimental stroke treatments. For example, an individual
with heart disease may be taking an ACE inhibitor, a β-
blocker, and a statin, or an elderly woman may be taking
calcium and vitamin D supplements for osteoporosis. The
updated STAIR recommendations mention the need for such
interaction studies with a therapeutic agent and medications
commonly used in stroke patients [5]. Indeed, having these
other bioactive compounds “on board” could profoundly
impact how the brain suffers and responds to stroke, as well
as the efficacy of a stroke treatment. A discussion of drugs
that are administered at the time of stroke treatment is in
the “Drug Administration: Amount and Polypharmacology”
subsection. Therefore, incorporating “comorbid drugs” into
preclinical studies could increase translation potential.
Collectively, to improve the likelihood of success in
clinical trials, the animal model chosen in testing a preclinical
stroke treatment should be appropriate for the stroke model
used while eliminating potential confounding species/strain
differences and by replication in a different species (as
suggested in the STAIR recommendations) [4] to further
define the therapy’s mechanism of action via specific positive
and negative genetically manipulated animals and to include
comorbid conditions and drugs in humans.
3. Stroke Model
There are many ischemic stroke induction models, often with
multiple variations and typically targeting the middle cere-
bral artery, available to the preclinical researcher including:
endothelin-1 application, electrocoagulation, intraluminal
filament (suture), clip or mechanical occlusion, photothrom-
bosis, embolic models including administration of an autol-
ogous blood clot embolus, and thrombin injection. Each of
these models has advantages and disadvantages, including
perhaps the most clinically relevant model of autologous
blood clot embolus that is associated with high variability
in size and location as well as potential early autolysis,
hemorrhage, and high mortality (reviewed by Macrae, 2011)
[18]. Additionally, a model has recently been described
using emboli made of “red” (erythrocyte/fibrin) clots, rather
than traditional “white” (platelet/fibrin) clots, which may
be more related to human stroke [19]. On the other
hand, photothrombosis is comparatively very reproducible
in infarct size and location, but is associated with increased
edema not seen in human stroke [18]. Unfortunately, none
of the models currently available can recapitulate all of
the complicated facets of human stroke. Indeed, it has
recently been proposed that the most commonly used type of
stroke models, transient mechanical vascular occlusion (e.g.,
intraluminal filament model), should be eliminated entirely
from preclinical stroke research. This argument was based
on the position that transient mechanical vascular occlu-
sion induces different pathophysiology and postischemic
recirculation mechanisms allowing for a longer therapeutic
window in experimental models than that available in
human stroke [20, 21]. However, although these models do
not perfectly replicate human stroke, some considerations
may increase translation potential including (1) the size
of infarct generated, (2) the duration of ischemia, and (3)
physiological monitoring.
3.1. The Size of Infarct Generated. Infarct size and location
can vary greatly between and sometimes within stroke
models, and global ischemia and models with very large
infarcts may not translate well. Comparatively, distal middle
cerebral artery occlusion and photothrombosis produce rel-
atively small cortical infarcts, whereas the suture model can
produce relatively large infarcts [18]. Large infarct models
may be unfavorable as they often more accurately represent
human malignant infarction than typical stroke [22]. This
may also be a concern with genetically modified animals
that have larger infarcts than wild types. Of particular
concern, large infarcts can result in the destruction or
the influence of tissue with regulatory roles (temperature,
hormones, etc.), which may confound the investigation.
For example, thalamic, hypothalamic, hippocampal, and
midbrain damage can occur in intra-arterial suture occlusion
(especially with occlusions greater than 60 min), which is
not seen in human stroke, and about 10% of mice develop
subarachnoid hemorrhage [22]. Another consequence of
very large infarcts is that animals may have a higher mortality
rate, which would select only the population of surviving
animals for outcome measures; however, properties that
allowed that population to survive (other than the variable
being tested) may confound the investigation and subsequent
translation potential. Therefore, mortality numbers and
causes should be reported. Finally, large infarcts may affect
different neuronal types than those that are typically directly
affected in human stroke. For example, if a treatment was
more neuroprotective in hippocampal than cortical neurons,
models that include hippocampal damage may show a
decrease in infarct size with treatment, but if that reduction
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is due to the protection of hippocampal neurons not
typically infarcted in human stroke, translation potential is
confounded. Therefore, focal ischemia may be preferred over
global ischemia and induction of smaller, more reproducible
infarcts preferred over larger infarcts. However, available
models that consistently produce small infarcts can also
have limitations. For example, photothrombosis results
in high vasogenic and cytotoxic edema more similar to
traumatic brain injury than human stroke [22]. Additionally,
reports of neuroprotection in very small infarcts may be
misleading because a large percent change in infarct size may
overestimate the benefit of a very small amount of salvaged
tissue. Furthermore, distal MCA infarct models may produce
small infarcts resulting in specific whisker barrel cortex
deficits that are difficult to assess. This can be somewhat
overcome by occluding the ipsilateral or both carotid arteries;
however, the resultant increase in mortality has led to the
development of a model that combines distal MCA occlusion
with 1 hour of hypoxia, termed “DH stroke” [23]. DH stroke
reportedly minimizes problems of Circle of Willis variability
in C57BL/6J mice, increases infarct size and behavioral
effects, without impacting the hippocampus or significantly
increasing mortality. Lastly, very small experimental infarcts
could potentially underestimate the size of typical human
ischemic stroke infarcts.
3.2. The Duration of Ischemia. How long a cerebral artery
is occluded should also be taken into consideration and is
reviewed in significant detail by Liu et al. [24]. In addition
to increasing infarct size beyond what is seen in humans,
prolonged occlusion may alter viable cell functioning of
the neurovascular unit beyond human stroke, which may
be difficult, if feasible, to detect. On the other hand,
permanent occlusion models do not include a reperfusion
injury component, which is likely relevant to stroke injury
in humans, and collateral vessels may develop and restore
blood flow to affected areas. Indeed, the rate of spontaneous
recanalization/reperfusion is significant in humans and
contributes to variability in pathophysiology and outcome
[19]. Furthermore, as thrombolytics and clot retrieval and
removal devices become even more effective, reperfusion
and potential reperfusion injury may become more frequent.
Therefore, to increase translation potential, an appropriate
model should be chosen that represents the human condition
with respect to the mechanisms of stroke being targeted and
the treatment’s proposed mechanism of action, especially
when the therapy may be conducive to administration with
tPA in humans.
3.3. Physiological Monitoring. Physiological parameters
including blood gases, blood pressure, blood glucose level,
body temperature, and cerebral blood flow (CBF) should
be assessed during and beyond the stroke model procedure.
For example, it is important to determine if an experimental
treatment is solely affecting stroke infarct size or recovery via
an indirect mechanism by altering physiological parameters
(e.g., neuroprotective hypothermia). Therefore, due to
inherent variability between and within models, researchers
should also report in detail the inclusion/exclusion criteria
used (including mortality), which may improve translation.
Importantly, one factor that could influence physiological
parameters is the anesthetic used, as some anesthetics are
associated with neuroprotection, hypothermia, dehydration,
or other effects [24–26]. Additionally, anesthetic effects
may vary between species/strains, interact with the therapy,
or influence the pathophysiology and response to stroke.
For example, ketamine is classified as an NMDA receptor
antagonist that has been found to interact at several other
off-target sites as well [27, 28]. Therefore, one could take
the perspective that stroke studies testing a neuroprotective
agent performed under anesthesia are actually testing a
combinatorial treatment of two drugs [8]. Therefore, we
suggest that experimental stroke results also be confirmed
with an alternative anesthetic. CBF can be monitored using
a laser Doppler system. Although the STAIR originally
recommended decreasing laser Doppler signal by ≥60%
to ensure appropriate ischemia [4], this seems too low
and too broad a range for validity and consistency as the
pathophysiology and responses to stroke could vary greatly
between, for example, 61% and 97% occlusions. Instead, we
suggest occlusions of ≥80–85% and for decreases in CBF to
be compared between treatment groups to assess whether
differences in CBF systematically correlate with outcome
measures. Additionally, for transient models CBF should be
monitored (1) before occlusion for a baseline reading, (2)
at the start of occlusion to obtain a satisfactory reduction in
CBF, (3) at the end of occlusion to ensure that the vessel has
remained occluded, and (4) at the beginning of reperfusion
to verify that an increase in CBF from the occluded value
is observed. Indeed, the STAIR update emphasized the
importance of documenting adequate sustained occlusion
and monitoring reperfusion by Doppler flow or perfusion
imaging [5]. Despite this importance of CBF monitoring,
Philip et al. reported that less than 30% of studies reported
monitoring CBF [6].
Collectively, to increase the translational potential for
human stroke therapy, the experimental stroke model should
be performed with an appropriate model to produce infarcts
that do not affect regulatory structures or induce side effects
not seen in humans. Furthermore, physiological parameters
should be monitored, especially CBF, to both validate the
stroke procedure itself and determine whether the treatment
has confounding effects on physiology.
4. Drug Administration
The (1) amount and polypharmacology, (2) timing, and
(3) route of drug/treatment administration are extremely
important not only for assessment of therapeutic efficacy in
experimental models, but also for translational potential.
4.1. Amount and Polypharmacology. The STAIR recommen-
dations place a strong emphasis on the need for researchers
to define pharmacokinetics and pharmacodynamics includ-
ing complete dose-response curves (preferably sigmoidal—
rather than bell—shaped) with additional minimum dose of
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effectiveness and maximum dose of tolerance from serum
levels and consistent minimum neuroprotective concentra-
tion [4, 5]. While these are extremely important for assessing
translation potential, at the laboratory level these studies
can be extremely time and resource costly and are likely not
feasible to perform without first showing strong evidence of
efficacy.
Another consideration is the use of the “cocktail
approach” or “polypharmacology,” also mentioned in the
STAIR recommendations [4], where treatment involves
modulation of multiple targets potentially with more than
one drug (not necessarily at the same time). Stankowski and
Gupta reviewed many of the early pathological mechanisms
of stroke and emphasized the need for a neurotherapeutic
that could interfere with several stroke processes at once
[29]. Although the combinatorial drug approach is rarely
used in laboratory stroke research, it has high potential and,
therefore, should perhaps attract more attention. Important
among combinatorial treatment testing will be novel treat-
ments in conjunction with clinically relevant tPA (or another
thrombolytic) [30, 31]. Indeed, given the perspective that
restoration of oxygen and glucose will always be the best
neuroprotective therapy for ischemic stroke, and that tPA
has many independent effects from thrombolysis (potentially
due to its formulation with L-arginine), potential advantages
and disadvantages of combinatorial therapy with tPA need
to be assessed [32]. As discussed earlier, another aspect
of the cocktail approach that should be considered is the
use of a proposed treatment when drugs used for comor-
bid conditions are already “on board” to detect potential
interactions that could be relevant in humans. Therefore,
other drugs could be given before the onset of experimental
stroke and still be “on board” following the stroke (modeling
comorbid drugs, discussed above), or given at the time
of stroke treatment (combinatorial, polypharmacology) in
conjunction with the experimental treatment under study.
Additionally, treatments that target different facets of stroke
by different mechanisms, targets, and/or time frames could
be combined for therapeutic benefit. For example, a drug
to counteract excitotoxicity could be used acutely after
stroke for the advantage of early neuroprotection but not
more chronically where it might potentially impair neuro-
plasticity needed for neurorepair, combined with an anti-
inflammatory agent at a later or overlapping time frame,
to avoid the limitation of inhibiting acute inflammatory
responses that are necessary to rev up defenses, but for the
advantage of reducing prolonged inflammation that may be
detrimental to repair. These benefits may also be generally
exploited by giving both a neuroprotective agent to reduce
damage and a restorative agent to promote repair. In short, if
the mechanisms of one drug are known, a second drug may
be used to compliment the first drug, potentially additively
or synergistically. However, with more drugs “on board” a
major concern is the potential for neutralizing or harmful
drug interactions and disruption of homeostatic balance,
which would need to be investigated in detail [32]. Therefore,
polypharmacology or the “cocktail approach” should be
investigated more often but done so with caution as it may be
a “high risk-high reward” approach to improve translation
potential.
4.2. Timing. Stroke pathophysiology, endogenous responses,
and opportunity for intervention are extremely time depen-
dent, and researchers should attempt to use clinically
relevant therapeutic windows in their preclinical studies of
potential stroke treatments. This may limit the relevance
of preconditioning and treatment concurrent with stroke
onset studies to specific strokes that could be predicted to
occur in a hospital/surgical environment, because we cannot
typically predict when a stroke will occur or typically initiate
immediate treatment. Indeed, the vast majority of stroke
patients do not make the 3–4.5 h therapeutic window of t-
PA, thereby diminishing the clinical relevance of therapies
administered within a couple of hours after stroke that
might otherwise have been relevant in humans. Additionally,
placing inpatients at risk of stroke on stroke “pretreat-
ment” drugs may not be practical given their conditions.
Furthermore, as stroke evolution and processes are not
only prolonged but change with time, preconditioning and
concurrent treatments may target pathology phases not
targetable at feasible treatment windows (false positive for
feasible therapeutic efficacy) and, conversely, may be limited
in their ability to affect chronic injury mechanisms or repair
(false negative for feasible therapeutic efficacy). Finally, an
additional complication is the phenomenon of “wake-up”
strokes, where the exact time of symptom onset may not
be known. Although tPA has traditionally not been given
to individuals who have suffered a wake-up stroke, recent
evidence reported by Manawadu et al. at the American Heart
Association International Stroke Conference (2012) suggests
that tPA has similar functional and safety outcomes as
compared to individuals treated 4.5 h after stroke onset [33].
Collectively, while stroke evolution varies between models, a
potentially translatable stroke treatment should perhaps aim
to have efficacy when administered at later time points, ≥3–
4.5 hours after injury in rodent models, and optimally with
defined earliest and latest effective treatment times, thereby
identifying relative rodent therapeutic windows as suggested
by the STAIR recommendations [4].
4.3. The Route of Administration. Clinically relevant routes
of administration, or effective routes of therapeutic admin-
istration that could safely/easily be used for a potential
stroke patient, should be considered for preclinical stroke
studies to increase translation potential. Although the route
chosen will depend on properties of the current form of the
treatment, and may be influenced by the integrity of the
blood brain barrier at the time of treatment administration
(although this barrier is significantly disrupted after stroke
potentially minimizing this particular concern), researchers
should consider that, for example, intraperitoneal (I.P.),
intravenous (I.V.), intramuscular (I.M.), subcutaneous, or
intranasal (among other potential administration routes) are
more clinically relevant than intracerebroventricular (I.C.V.)
or intrathecal routes, which are used to more directly target
treatments to the site of stroke injury. As patients have
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Figure 1: Summary of considerations for successfully climbing the STAIR.
I.V. access established in the hospital setting, and I.P., I.M.,
subcutaneous, or intranasal administration is relatively easy
to accomplish, these methods are preferred over potentially
damaging routes used in animals. Importantly, oral adminis-
tration, although convenient, may be less clinically relevant
if a patient is unconscious, has difficulty swallowing, or
requires imminent surgery. Therefore, if an experimental
stroke treatment could not be given via a clinically relevant
route, researchers might consider additional or alternative
methods. For example, reducing the chemical structure of
the treatment to a smaller size that retains efficacy but
achieves better distribution, using a similar treatment that
operates via the same signal transduction mechanisms at the
same level, or using a downstream effector of the treatment
that operates via the same mechanism at a lower signal
transduction level and can be given via a clinically relevant
route.
Collectively, preclinical stroke studies of potential new
treatments should be performed to identify the pharmacoki-
netics and pharmacodynamics of the treatment including
dose response curves as much as practically possible, poten-
tially with less emphasis on preconditioning or treatment
administration at time of injury, with more efforts for
“cocktail approaches” especially with “comorbid” drugs and
with clinically relevant routes of administration.
5. Outcome Measures
The two most important and most commonly performed
outcome measures, emphasized in the STAIR recommenda-
tions as both essential assessments [4], are measurement of
infarct volume and sensorimotor function tests. These are
both critical to perform in a valid manner to increase trans-
lation potential of preclinical stroke studies. Additionally,
it is essential that the individual performing the outcome
measures is blind to the treatment of each animal, and testing
should be randomized. Indeed, the STAIR recommends
reporting sample size calculations, proper randomization,
and allocation concealment; however, Philip et al. reported
that only 10% of studies reported whether the investigator
was blinded during treatment administration [5, 6]. Like-
wise, a systematic analysis of all studies published in The
Journal of Cerebral Blood Flow and Metabolism in 2008
recently showed that of animal studies, only 22% reported
randomization, 8% allocation concealment, 15% blinded
assessment of outcome, and 14% inclusion/exclusion criteria
[34]. It will be critical to improve upon these measures and
report them to ensure research validity.
5.1. Measurement of Infarct Volume. The most common
measurements of preclinical experimental infarct volume
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are determined from brain tissue histologically stained
with triphenyl tetrazolium chloride (TTC), hematoxylin
and eosin (H&E), nissl, or cresyl violet. TTC staining may
be accurately used through poststroke day 7 [35], but is
unreliable at later time points as infarct infiltration of
inflammatory cells may confound measurement (by making
the infarct artificially appear smaller). Furthermore, when
quantifying infarct volume, a correction factor should be
applied based on the swelling of the ipsilateral (stroked)
hemisphere and apparent infarct so that infarct size quan-
tification is not confounded by volumetric changes due only
to swelling, of which edema is a major factor.
5.2. Sensorimotor Function Tests. The appropriate choice of
functional tests in preclinical studies is also essential for
increasing the translational potential of a stroke treatment.
Common functional tests include the cylinder test, paw-
placement reflex tests, ladder tests, beam tests, the grid-
walking test, reaching tasks, and the rotarod task, among
others. Each of these tests has advantages and disadvantages
and which to choose will ultimately depend on the stroke
model used (e.g., a stroke model that results in paw
motor deficits should be followed by tests that involve
paw movement, etc.) and resultant dysfunction displayed.
General recommendations include randomized testing by
the same tester who is trained to perform the tests validly
and consistently, who is blinded to the treatment condition
of animals (to optimize reproducibility and minimize bias),
and reducing tester subjectivity by using more simple and
natural tasks that minimize anxiety, fear, or hyperactivity
of the animal. For example, a test in which a reflex-paw
placement is elicited by touching the ipsilateral vibrissae on a
hard surface may be complicated in mice due to the animal’s
resistance to being positioned in such a way, resulting in
variability in animal mobility, temperament, motivation, and
so forth, collectively resulting in unreliable measurements.
Also, some reaching tasks involving food deprivation may
introduce confounds associated with being food deprived,
including hormone and motivation changes, in addition to
potential confounding hunger changes from the drug. Thus,
in agreement with the STAIR, researchers should perform
more than one behavioral test that is distinct, sensitive to
the deficit, and minimizes confounding influence on the
animal.
The duration of sensorimotor testing is also an impor-
tant consideration to ensure stable outcomes. Although
the original STAIR recommendations mention that many
preclinical studies only assess outcomes 1 day after ischemia,
it appears that researchers now typically assess behavior for
longer time periods after stroke onset. Prolonged testing is
important as at 1 day after ischemia the infarct size has
often not fully evolved in many stroke models, and outcomes
are not stable. Additionally, some therapies may have early
poststroke benefits that are later reversed or do not affect later
phase detrimental mechanisms. Therefore, we recommend
that when possible, functional testing should be carried out
for at least 2 to 3 weeks after injury and longer if one or more
groups do not have stable function. Finally, experimental
animals possess some spontaneous recovery from stroke-
induced sensorimotor dysfunction that can be quite robust;
therefore, the effect of the treatment must be verified as
distinct from spontaneous recovery.
The selection and necessity of other outcome measures
depends on the treatment’s proposed mechanism of action.
For example, a proposed antiinflammatory mechanism
might have outcome measures assessing inflammatory cells,
markers, signals, and so forth. whereas an anti-apoptotic
agent might perform TUNEL, caspase-3 cleavage, Annexin-
V stains, and so forth. Additionally, these endpoints may be
of high clinical relevance if translated as relevant biomarkers
that could be measured directly or indirectly in humans, as
suggested in the updated STAIR recommendations [5].
Collectively, outcome measures should include blinded
volumetric measurement of the infarct area using the appro-
priate stain with correction for swelling, and at least two
distinct sensorimotor function tests selected for sensitivity
to the specific deficits, conducted in a manner to minimize
tester bias and confounding influence on the animal, and
performed for a prolonged duration to ensure outcome
stability.
6. Conclusions
To increase the potential of laboratory experimental stroke
treatments to translate to successful clinical trials, researchers
have many factors to consider. These considerations, sum-
marized in Figure 1, should include the animal model,
stroke model, drug administration, and outcome measures to
ensure that each aspect is as clinically relevant as practically
possible. In general, replication of findings in multiple
stroke models by multiple independent investigators is
strongly encouraged, as suggested in the updated STAIR
recommendations. While these considerations and STAIR
may seem steep, the end results of potential translational
success are worth the climb.
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